TRIALSITEIQ PUBLIC FEASIBILITY SCORECARD · GRADE D-

NCT06907043: A Study of PARP1 Selective Inhibitor, EIK1004 (IMP1707) in Participants With Advanced Solid Tumors.

Sponsor: Eikon Therapeutics · Phase: PHASE1/PHASE2 · Area: ONCOLOGY · Target Enrollment: 130 pts

Competing Trials Overlap

8 Active Trials

Excess Burn Exposure

$4,241,160

Rescue Site Savings

+$2,788,170

Unlock Full NCT06907043 Backup Super-Site Packet ($49 One-Time Pass)

Download the complete list of top-decile low-cannibalization clinical sites, verified Principal Investigator (PI) direct emails/phones, and protocol optimization benchmarks.

Download $49 NCT06907043 Rescue Dossier →